Articles related to DEPRESSION

Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

Natural language processing models analyzing speech from children ages 9 to 13 predicted future mental health conditions more accurately than expert-rated stress assessments. Findings suggest linguistic patterns may serve as an early risk signal, though validation in larger cohorts is still needed.

Female mice recovering from a single ketamine exposure demonstrated microglia-driven neuroplasticity through FKBP51 activation, while male mice did not. The findings identify a sex-specific biologic pathway in a preclinical model, and human relevance remains unconfirmed.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.